Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies
暂无分享,去创建一个
A. Fischer | N. Mahlaoui | P. Lévy | O. Hermine | J. Beauté | F. Suarez | Y. Dudoit | M. Debré | N. Aladjidi | I. Pellier | P. Lévy | V. Millet | A. Tajahmady | C. Thomas | C. Thomas | L. Mignot | L. Le Mignot | Anne‐Marie Fischer | J. Beaute
[1] K. Cimon,et al. Economic assessment of different modalities of immunoglobulin replacement therapy. , 2008, Immunology and allergy clinics of North America.
[2] M. Conley,et al. Adults With X-Linked Agammaglobulinemia: Impact of Disease on Daily Lives, Quality of Life, Educational and Socioeconomic Status, Knowledge of Inheritance, and Reproductive Attitudes , 2008, Medicine.
[3] É. Oksenhendler,et al. Infections in 252 patients with common variable immunodeficiency. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] L. Hammarström,et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies , 2008, Clinical and experimental immunology.
[5] M. Berger. Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency , 2008, Immunology and Allergy Clinics of North America.
[6] A. Fasth,et al. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency , 2007, Acta paediatrica.
[7] Shigeaki Nonoyama,et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. , 2007, The Journal of allergy and clinical immunology.
[8] S. Stanworth,et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review , 2007, Clinical and experimental immunology.
[9] A N N Gardulf,et al. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies , 2006, Current opinion in allergy and clinical immunology.
[10] E. Hachulla,et al. Étude comparative du coût du traitement à domicile des immunoglobulines intraveineuses ou sous-cutanées à visée substitutive , 2006 .
[11] H. Ochs,et al. Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases , 2006, Journal of Clinical Immunology.
[12] M. Atkinson,et al. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] M. Bellanger,et al. The “Health Benefit Basket” in France , 2005, The European Journal of Health Economics.
[14] M. Atkinson,et al. Health and Quality of Life Outcomes , 2004 .
[15] D. Ericson,et al. The Comparison of the Efficacy and Safety of Intravenous Versus Subcutaneous Immunoglobulin Replacement Therapy , 2000, Journal of Clinical Immunology.
[16] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[17] L. Hammarström,et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs , 1995, The Lancet.
[18] M. Stano,et al. The Economics of Health and Health Care : International Student Edition, 8th Edition , 1993 .
[19] R. Proujansky. Immunologic Disorders in Infants and Children , 1990 .
[20] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[21] M. Lischner. Immunologic disorders in infants and children , 1974 .
[22] H. Ochs,et al. Health-Related Quality of Life and Treatment Satisfaction in North American Patients with Primary Immunedeficiency Diseases Receiving Subcutaneous IgG Self-Infusions at Home , 2006, Journal of Clinical Immunology.
[23] E. Hachulla,et al. [Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution]. , 2006, La Revue de medecine interne.
[24] M. Borte,et al. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance , 2005, The European Journal of Health Economics.
[25] C. Kallenberg,et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. , 2001, Annals of internal medicine.